Synergistic Activity of Noble Trimetallic Nanofluids: Unveiling Unprecedented Antimicrobial Potential and Computational Insights.

Nanofluids hold significant promise in diverse applications, particularly in biomedicine, where noble trimetallic nanofluids outperformed their monometallic counterparts. The composition, morphology, and size of these nanofluids play pivotal roles in their functionality. Controlled synthesis methods have garnered attention, focusing on precise morphology, content, biocompatibility, and versatile chemistry. Understanding how reaction parameters such as time, reducing agents, stabilizers, precursor concentration, temperature, and pH affect size and shape during synthesis is crucial. Trimetallic nanofluids, with their ideal composition, size, surface structure, and synergistic properties, are gaining traction in antimicrobial applications. These nanofluids were tested against seven microorganisms, demonstrating a heightened antimicrobial efficacy. Computational analyses, including molecular docking, dynamics, density functional theory (DFT), molecular electrostatic potential (MESP) analysis, and absorption, distribution, metabolism, elimination, and toxicology studies (ADMET) provided insights into binding interactions, energy, reactivity, and safety profiles, affirming the antimicrobial potential of trimetallic nanofluids. These findings emphasize the importance of controlled synthesis and computational validation in harnessing the unique properties of trimetallic nanofluids for biomedical applications.

High-Entropy Alloys for Solid Hydrogen Storage: Potentials and Prospects.

Hydrogen storage is one of the most significant research areas for exploiting hydrogen energy economy. To store hydrogen with a high gravimetric/volumetric density, gaseous hydrogen storage systems require a very high-pressure compressed gas cylinder which is quite unsafe and the storage in the liquid form needs cryogenic containers to be maintained at roughly 20 K under ambient pressure because hydrogen has a very low critical temperature of 33 K. However, hydrogen can be stored in solid materials with higher concentration of hydrogen compared to the gaseous and liquid hydrogen storage systems. It is therefore, worthwhile to look into the experimental and theoretical research on prospective hydrogen storage materials. The hydride-forming alloys and intermetallic compounds are found to be the most important families of hydrogen storage materials. Multicomponent alloys consisting of five or more principal elements, also known as high-entropy alloys appear to have potential for the development as hydrogen storage materials. Hydride-forming elements like Ti, Zr, V, Nb, Hf, Ta, La, Ce, Ni, and others have been shown to have hydrogen storage properties and the ability to produce single-phase high-entropy intermetallics. Here, attempts will be made to present a short review on utilization of multicomponent high-entropy alloys as solid hydrogen storage materials. Furthermore, we will also present some of our work on the synthesis, structural-microstructural characterization and hydrogen storage properties of Ti-Zr-V-Cr-Ni equi-atomic hydride-forming high-entropy alloys. From the preliminary investigation, the maximum storage capacity in this system was observed to be 1.78 wt%, which is comparable to other hydrogen storage materials. The prospects of high-entropy-based alloys for hydrogen storage will be discussed.

Friction of magnetene, a non-van der Waals 2D material.

Two-dimensional (2D) materials are known to have low-friction interfaces by reducing the energy dissipated by sliding contacts. While this is often attributed to van der Waals (vdW) bonding of 2D materials, nanoscale and quantum confinement effects can also act to modify the atomic interactions of a 2D material, producing unique interfacial properties. Here, we demonstrate the low-friction behavior of magnetene, a non-vdW 2D material obtained via the exfoliation of magnetite, showing statistically similar friction to benchmark vdW 2D materials. We find that this low friction is due to 2D confinement effects of minimized potential energy surface corrugation, lowered valence states reducing surface adsorbates, and forbidden low-damping phonon modes, all of which contribute to producing a low-friction 2D material.

Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review.

There have been over seven million cases and almost 413 372 deaths globally due to the novel coronavirus (2019-nCoV) associated disease COVID-19, as of 11 June 2020. Phylogenetic analysis suggests that there is a common source for these infections. The overall sequence similarities between the spike protein of 2019-nCoV and that of SARS-CoV are known to be around 76% to 78% and 73% to 76% for the whole protein and receptor-binding domain (RBD), respectively. Thus, they have the potential to serve as the drug and/or vaccine candidate. However, the individual response against 2019-nCoV differs due to genetic variations in the human population. Understanding the variations in angiotensin-converting enzyme 2 (ACE2) and human leukocyte antigen (HLA) that may affect the severity of 2019-nCoV infection could help in identifying individuals at a higher risk from the COVID-19. A number of potential drugs/vaccines as well as antibody/cytokine-based therapeutics are in various developmental stages of preclinical/clinical trials against SARS-CoV, MERS-CoV, and 2019-nCoV with substantial cross-reactivity, and may be used against COVID-19. For diagnosis, the reverse-transcription polymerase chain reaction is the gold standard test for initial diagnosis of COVID-19. A kit based on serological tests are also recommended for investigating the spread of COVID-19 but this is challenging due to the antibodies cross-reactivity. This review comprehensively summarizes the recent reports available regarding the host-pathogen interaction, morphological and genomic structure of the virus, and the diagnostic techniques as well as the available potential therapeutics against COVID-19.

Extraction of Two-Dimensional Aluminum Alloys from Decagonal Quasicrystals.

Atomically thin metallic alloys are receiving increased attention due to their prospective applications as interconnects/contacts in two-dimensional (2D) circuits, sensors, and catalysts, among others. In this work, we demonstrate an easily scalable technique for the synthesis of 2D metallic alloys from their 3D quasicrystalline precursors. We have used aluminum (Al)-based single-phase decagonal quasicrystal Al66Co17Cu17 alloy to extract the corresponding 2D alloy structure. The 2D layered Al alloy possesses 2-fold decagonal quasicrystalline symmetry and consists of two- or three-layer-thick sheets with a lateral dimension of microns. These 2D metallic layers were combined with the atomic layers of tungsten disulfide to form the stacked heterostructures, which is demonstrated to be a stable and efficient catalyst for hydrogen evolution reaction.

Nanonization increases the antileishmanial efficacy of amphotericin B: an ex vivo approach.

With widespread resistance to pentavalent antimonial in the endemic eastern terai belt of Nepal and Bihar, India, Amphotericin B deoxycholate is now the first-line antileishmanial drug for the treatment of visceral leishmaniasis (VL). However, universal occurrence of infusion-related fever and rigors with amphotericin B (AmB), occasional serious life-threatening toxicities like cardiotoxicity, anaphylaxis, hypokalemia, and nephrotoxicity are major barriers to its use in areas with limited medical facilities. Liposomal amphotericins, however, are devoid of adverse effects, high cost makes it unaffordable. We had formulated nanoparticles (10-20 nm) from amphotericin B deoxycholate (1-2 µm) applying high pressure (150 atm) milling homogenization in argon atmosphere and tested its ex vivo efficacy in Leishmania infected J774A cell line and peritoneal macrophage. The ex vivo ED50 for intracellular amastigotes in peritoneal macrophage by nano-amphotericin was 0.0027 ± 0.001 µg/mL which was significantly less (p = 0.0029) than the required dose of amphotericin B (0.0426 ± 0.003 µg/mL). Similarly, in J774A cell line, 50 % of intracellular amastigotes were cleared by 0.0038 ± 0.001 µg/mL of nano-amphotericin while the dose was a bit more for AmB (0.0196 ± 0.001 µg/mL) illustrating the significant difference (p value, 0.0122). The nanoformulation has also shown high efficacy (ED50, 0.0028-0.0035 µg/mL) in inhibition of infected macrophage count. The new formulation accumulated to spleen, the targeted organ, 7 days after inoculation of drug to the infected hamster as traced in vivo by TEM convincing it as potential drug. Given a favorable safety profile and very low cost of production contemplated, it may prove to be a feasible alternative for conventional amphotericin B.

An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis.

Amphotericin B (AmB), is a highly effective antileishmanial agent used as first-line treatment in different formulations in visceral leishmaniasis endemic areas of Bihar, India. However, parenteral infusion, prolonged hospitalization, and toxicity are major hurdles. Our previous work demonstrated the efficacy and stability of functionalized carbon nanotubes as a delivery mechanism for AmB. In this study, using the hamster model, we have shown that this novel formulation of AmB can be administered orally, resulting in 99% inhibition of parasite growth following a 5-day course at 15 mg/kg body weight.

Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.

OBJECTIVES: This study describes the antileishmanial efficacy of the novel drug formulation of amphotericin B (AmB) attached to functionalized carbon nanotubes (f-CNTs) and compares it with AmB. METHODS: f-CNTs were prepared in a two-step chemical carboxylation and amidation process. The AmB was then attached to make f-CNT-AmB and its construction was confirmed by Fourier transform infrared (FTIR) spectroscopy and transmission electron microscopy (TEM). The cytotoxicity of the constructed compound, f-CNT-AmB, was assessed in vitro using the J774A.1 macrophage cell line and in vivo using healthy BALB/c mice. Antileishmanial activity of AmB and f-CNT-AmB was assessed in vitro using a macrophage (J774A.1 cell line) model of Leishmania donovani infection. Antileishmanial activity was assessed in vivo by comparing the parasite load of hamsters treated with a 5 day course of AmB, f-CNTs or f-CNT-AmB initiated at 30 days after infection with L. donovani parasites. RESULTS: The FTIR spectroscopy and TEM data demonstrate the successful attachment of AmB to f-CNTs. The in vitro cytotoxicity of AmB, f-CNTs and f-CNT-AmB was measured by the cytotoxic concentration required to kill 50% of the cells: 0.48±0.06 µg/mL; 7.31±1.16 µg/mL; 0.66±0.17 µg/mL, respectively, in the J774A.1 cell line. The in vivo toxicity assessment of the compounds in BALB/c mice revealed no hepatic or renal toxicity. Against intracellular amastigotes the in vitro antileishmanial efficacy of f-CNT-AmB was significantly higher than that of AmB (IC50 0.00234±0.00075 µg/mL versus 0.03263±0.00123 µg/mL; P≤0.0001). The percentage inhibition of amastigote replication in hamsters treated with f-CNT-AmB was significantly more than that with AmB (89.85%±2.93% versus 68.97%±1.84%; P=0.0004). CONCLUSIONS: The results of these experiments clearly demonstrate that f-CNT-AmB has significantly greater antileishmanial efficacy than AmB and had no significant cytotoxic effects.

Antileishmanial activity of nano-amphotericin B deoxycholate.

OBJECTIVES: The aim of the present study was to compare the efficacy of a nano form of amphotericin B deoxycholate with that of conventional amphotericin B deoxycholate for the treatment of visceral leishmaniasis. METHODS: We have formulated nanoparticles (10-20 nM) from amphotericin B deoxycholate (1-2 microM) by applying high-pressure (150 argon) milling homogenization and have tested their efficacy in a J774A cell line and in hamsters. Parasite survival and tissue burden in spleen were evaluated for nano-amphotericin B and conventional amphotericin B. Both nano-amphotericin B and conventional amphotericin B were injected intraperitoneally at 5 mg/kg per day for 5 days. RESULTS: The inhibition of amastigotes in the splenic tissue with nano-amphotericin B was significantly more than with conventional amphotericin B (92.18% versus 74.57%, P = 0.005). Similarly, the suppression of parasite replication in the spleen was also found to be significant (99.18% versus 97.17%, P = 0.05). In a cytotoxicity test, nano-amphotericin B against the J774A cell line had a CC(50) of 12.67 mg/L in comparison with 10.61 mg/L for amphotericin B, far higher than the doses used for ED(50). CONCLUSIONS: Nanoparticles of amphotericin B had significantly greater efficacy than conventional amphotericin B. This formulation may have a favourable safety profile, and if production costs are low, it may prove to be a feasible alternative to conventional amphotericin B.